Research and Markets: PARP Inhibitors - A New Class of Targeted Cancer Therapies

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/8kct3p/parp_inhibitors) has announced the addition of the "PARP Inhibitors - A new class of targeted cancer therapies" report to their offering.

Poly (ADP-ribose) polymerase (PARP) enzymes are involved in repairing DNA. PARP inhibition leads to synthetic lethality because only an error prone repair pathway is left to repair DNA damage. For this reason, PARP inhibitors are a promising new class of targeted cancer therapies being developed to treat cancers with inherited or acquired defects in DNA repair pathways.

In particular, BRCA-1 or BRCA-2 mutations affect the repair of double-strand DNA breaks and lead to genomic instability and malignant progression. So carriers of BRCA mutations are particularly sensitive to PARP inhibitors. Other mutations in genes required for DNA repair have effects similar to those of BRCA 1-2 mutations.

PARP inhibitors are in development include:

  • Olaparib (Astra Zeneca)
  • Niraparib (Tesaro and Merck)
  • BMN-673 (BioMarin)
  • Rucaparib (Clovis Oncology)
  • Veliparib (ABT-888; AbbVie and Abbott)

PARP inhibitor development has gone through ups and downs in recent years. We describe the issues and hurdles that have impeded development. Though monotherapy is targeted only to mutation carriers, combinations with chemotherapy agents and/or radiotherapy that induce DNA defects would significantly expand the target population for treatment with PARP inhibitors. However, combination regimens tested thus far have shown increased dose-limiting hematologic toxicities. Although large controlled trials are necessary to clearly pick winners, we describe emerging trends from early stage data.

Key Topics Covered:

  1. Why so much interest in PARP inhibitors?
  2. Gene Repair and Cancer
  3. Ovarian cancer
  4. BRCA 1-2 mutant Breast Cancer
  5. PARP inhibitors in clinical development
  6. Opinion
  7. Marketing opportunity in ovarian cancer
  8. Marketing opportunity in breast cancer
  9. Summary Opinion

For more information visit http://www.researchandmarkets.com/research/8kct3p/parp_inhibitors

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals